Adding tenapanor to phosphate binders for people on dialysis with high phosphorus
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study tests whether adding a medication called tenapanor (which helps reduce phosphorus absorption in the gut) to your current phosphate binder can improve blood phosphorus levels in people on hemodialysis. It aims to find a safe and effective way to lower phosphorus, which is important for bone and heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You are on regular hemodialysis (about 3 times a week, 4 hours each session) for at least 3 months.
- You have been taking a phosphate binder (a medicine that lowers phosphorus) for at least 3 weeks on a stable dose.
- Your blood phosphorus level is above 4.5 mg/dL (your doctor will check this).
- You should not have had diarrhea in the last week, and you should not have inflammatory bowel disease or irritable bowel syndrome with diarrhea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called TS-172 can help lower phosphorus levels in patients on peritoneal dialysis (a type of kidney treatment). High phosphorus can cause bone problems and other complications, so the trial aims to see if this drug works better than current treatments.
This trial tests a new drug called AP301 to lower high phosphate levels in people on dialysis. It's designed to help control phosphate, which can be hard to manage with diet and current medications.
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
This trial tests a new medicine called TS-172 for people with high phosphorus levels who are on hemodialysis. It aims to lower phosphorus levels and is taken along with your current phosphate binder medication.
This trial tests a new drug, JMKX003002, to lower high phosphorus levels in people with end-stage kidney disease who are on hemodialysis. If you have trouble controlling your phosphorus, this treatment might help.
This trial compares two treatment goals for blood phosphate levels in people with end-stage kidney disease who are on dialysis. It may help determine which target is safer and works better in real-world care.
Hear when a new CKD 5D, Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.